Skip to main content
SpringerLink
Log in

Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

In the present study we set out to explain the complex atropine dose-response curves in man in relation to M-cholinoceptor subtype occupancy. In healthy volunteers the effects of atropine on heart rate and salivary flow were quantified. M-cholinoceptor subtype occupancy by antagonist present in plasma samples was detected in an in vitro radioreceptor assay. Atropine effects were studied without and after propranolol (240 mg oral dose) and without and after pirenzepine (1.1 mg i. v.) to differentiate β-adrenoceptor and M-cholinoceptor subtype mediated effects.

  1. 1.

    In receptor binding studies, M-cholinoceptors in bovine cerebral cortex membranes were labelled with 3H-pirenzepine (pK d = 8.05), M-cholinoceptors in rat salivary gland membranes with 3H-N-methylscopolamine (pK d = 9.02). Atropine competed for binding of these ligands with a small (2.1-fold) preferential selectivity via the cerebral in comparison to the glandular receptors (pK i = 9.18 versus 8.86). Pirenzepine showed a marked selectivity (40-fold) in this respect with pK i-values of 8.05 (M1: cerebral cortex) and 6.45 (M2: salivary glands).

  2. 2.

    At heart rate and at salivary flow, bivalent dose-response curves of atropine were observed with opposite effect vectors. The typical antagonist effects at M-cholinoceptors (i. e. an increase of heart rate and an inhibition of salivary flow) were observed at doses > 1 μg/kg, whereas “paradoxical” cholinomimetic effects of atropine became apparent at lower doses. From a superposition of two isotherms with opposite effect vectors ED50-values were calculated, which were in the range of half-maximal M-cholinoceptor occupancy in the in vitro radioreceptor assay of plasma samples.

  3. 3.

    The time-dependent decline of atropine effects after the highest dose (40 μg/kg) and the respective in vitro M-cholinoceptor occupancy were in good agreement with the dose-response data.

  4. 4.

    β-Adrenoceptor blockade did not influence the pattern of the atropine dose-response relation. After pirenzepine (∼ 70% of M1-cholinoceptor occupancy), the cholinomimetic effects of atropine were abolished and only monovalent atropine dose-response curves were observed. Maximal effects of atropine were not different in comparison to the respective controls without pirenzepine.

  5. 5.

    The standard deviation of the RR-intervals in the ECG as a measure of postsynaptic M-cholinoceptor stimulation was increased after pirenzepine by 58% and decreased after the maximum atropine dose by 85%.

It is concluded, that the cholinomimetic effects observed after atropine result from its antagonism at peripheral M1-cholinoceptors. A negative feedback mechanism of acetylcholine release via M1-autoreceptors is discussed as a possible mechanism involved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ashford A, Penn GB, Ross JW (1962) Cholinergic activity of atropine. Nature 193:1082–1083

    Google Scholar 

  • Birdsall NJM, Hulme EC (1983) Muscarinic receptor subclasses. Trends in Pharmacol Sci 4:459–463

    Google Scholar 

  • Carmine AA, Brogden RN (1985) Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30:85–126

    Google Scholar 

  • Chamberlain DA, Turner P, Sneddon JM (1967) Effects of atropine on heart-rate in healthy man. Lancet 2:12–15

    Google Scholar 

  • Das G, Talmers FN, Weissler AM (1975) New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man. Am J Cardiol 36:281–285

    Google Scholar 

  • Dibner-Dunlap ME, Eckberg DL, Magid NM, Cintron-Trevino NM (1985) The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine. Circulation 71:797–804

    Google Scholar 

  • Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S (1975) Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19:11–17

    Google Scholar 

  • Eglen RM, Whiting RL (1986) Muscarinic receptor subtypes: a critique of the current classification and a proposal for a working nomenclature. J Anton Pharmacol 5:323–346

    Google Scholar 

  • Fink M, Irwin P (1980) EEG and behavioral effects of pirenzepine in normal volunteers. Scand J Gastroent 15 (Suppl 66):40–46

    Google Scholar 

  • Fouad FM, Tarazi RC, Ferrario CM, Fighaly S, Alicandri C (1984) Assessment of parasympathetic control of heart rate by a noninvasive method. Am J Physiol 246: H834-H842

    Google Scholar 

  • Fuder H, Rink D, Muscholl E (1982) Sympathetic nerve stimulation on the perfused heart. Affinities of N-methylatropine and pirenzepine at pre- and postsynaptic muscarine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 318:210–219

    Google Scholar 

  • Gaddum JH (1957) Theories of drug antagonism. Pharmacol Rev 9:211–218

    Google Scholar 

  • Giraldo E, Monferini E, Hammer R (1985) Selective labelling of M1-receptors in autonomic ganglia with 3H-pirenzepine. Drug Res 35(I):325–328

    Google Scholar 

  • Hammer R, Giachetti A (1982) Muscarinic receptor subtypes: M1 and M2. Biochemical and functional characterization. Life Sci 31:2991–2998

    Google Scholar 

  • Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980) Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90–92

    Google Scholar 

  • Hirschowitz BI, Fong J, Molina E (1983) Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog. J Pharmacol Exp Ther 225:263–268

    Google Scholar 

  • Jaup BH, Blomstrand Ch (1980) Cerebro-spinal fluid concentration of pirenzepine after therapeutic dosage. Scand J Gastroent 15 (Suppl 66):35–37

    Google Scholar 

  • Jaup BH (1981) Studies on the mode of action of pirenzepine in man with special reference to it's anticholinergic muscarinic properties. Scand J Gastroent 16 (Suppl 68):1–26

    Google Scholar 

  • Jeck D, Lindmar R, Löffelholz K, Wanke M (1987) The effect of pirenzepine (PZ) and (+)-tubocurarine (TC) on the release of acetylcholine (ACh) from the perfused chicken heart. Naunyn-Schmiedeberg's Arch Pharmacol 335 (Suppl):R77

    Google Scholar 

  • Kaumann AJ, Hennekes R (1979) The affinity of atropine for muscarine receptors in human sphincter pupillae. Naunyn-Schmiedeberg's Arch Pharmacol 306:209–211

    Google Scholar 

  • Kilbinger H, Halim S, Lambrecht G, Weiler W, Wessler I (1984) Comparison of affinities of muscarinic antagonists to pre- and post junctional receptors in the guinea-pig ileum. Eur J Pharmacol 103:313–320

    Google Scholar 

  • Kottmeier CA, Gravenstein JS (1968) The parasympathomimetic activity of atropine and atropine methylbromide. Anesthesiology 29:1125–1133

    Google Scholar 

  • Löffelholz K, Pappano A (1985) The parasympathetic neuroeffector junction of the heart. Pharmacol Rev 37:1–24

    Google Scholar 

  • Morton HJV, Thomas ET (1958) Effect of atropine on the heart rate. Lancet 2:1313–1315

    Google Scholar 

  • Muscholl E (1980) From the cholinergic link to the cholinergic antilink in adrenergic transmission. Trends in Pharmacol Sci 1:381–382

    Google Scholar 

  • Mutschler E, Lambrecht G (1984) Selective muscarinic agonists and antagonists in functional tests. Trends in Pharmacol Sci 5 (Suppl):39–44

    Google Scholar 

  • Potter LT, Flynn DD, Hanchett HE, Kalinoski DL, Luber-Narod J, Mash DC (1984) Independent M1 and M2 receptors: ligands, autoradiography and functions. Trends in Pharmacol Sci 5 (Suppl):22–31

    Google Scholar 

  • Schild HO (1947) The use of drug antagonists for the identification and classification of drugs. Br J Pharmacol 2:251–258

    Google Scholar 

  • Starke K (1981) Presynaptic receptors. Ann Rev Pharmacol Toxicol 21:7–30

    Google Scholar 

  • Van Hooff M, Van Baak M, Schols M, Rahn KH (1984) Studies of salivary flow in borderline hypertension: effects of drugs acting on structures innervated by the autonomic nervous system. Clin Sci 66:599–604

    Google Scholar 

  • Wellstein A, Palm D, Wiemer G, Schäfer-Korting M, Mutschler E (1984) Simple and reliable radioreceptor assay for β-adrenoceptor antagonists and active metabolites in native human plasma. Eur J Clin Pharmacol 27:545–553

    Google Scholar 

  • Wellstein A, Palm D, Beltz GG, Pitschner HF (1985) Receptor binding of propranolol is the missing link between plasma concentration kinetics and effect time course in man. Eur J Clin Pharmacol 29:131–147

    Google Scholar 

  • Wellstein A, Pitschner HIT, Palm D (1986a) M-Cholinoceptors of rat salivary gland as a model to explain atropine effects in man. Naunyn-Schmiedeberg's Arch Pharmacol 334 (Suppl):R45

    Google Scholar 

  • Wellstein A, Palm D, Belz GG, Leopold G, Bühring KU, Pabst J (1986b) Concentration kinetics of propranolol, bisoprolol and atenolol in man assessed with chemical detection and a subtype selective β-adrenoceptor assay. J Cardiovasc Pharmacol 8 (Suppl 11): S41-S47

    Google Scholar 

  • Wellstein A, Pitschner HF, Palm D (1987) Pirenzepine dose-response curves in man in comparison to M1- and M2-cholinoceptor occupancy in vitro. Naunyn-Schmiedeberg's Arch Pharmacol 335 (Suppl):R80

    Google Scholar 

  • Wetzel GT, Brown JH (1985) Presynaptic modulation of acetylcholine release from cardiac parasympathetic neurons. Am J Physiol 248:H33-H39

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum der Pharmakologie, Klinikum der J. W. Goethe-Universität, Theodor-Stern-Kai 7, D-6000, Frankfurt 70, Federal Republic of Germany

    A. Wellstein

  2. Kerckhoff-Klinik der Max-Planck-Gesellschaft, D-6350, Bad Nauheim, Federal Republic of Germany

    H. F. Pitschner

Authors
  1. A. Wellstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. F. Pitschner
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Parts of the results were reported at the Fall Meeting 1986 and the Spring Meeting 1987 of the Deutsche Gesellschaft für Pharmakologie und Toxikologie (Wellstein et al. 1986a and 1987)

Send offprint requests to A. Wellstein at the above address

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wellstein, A., Pitschner, H.F. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 338, 19–27 (1988). https://doi.org/10.1007/BF00168807

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00168807

Key words

Search

Navigation